Search
Phleum pratense pollen
go.drugbank.com/drugs/DB10394ApprovedInvestigationalPhleum pratense pollen allergenic extract is used in allergenic testing.
Categories: Complex MixturesPitavastatin
go.drugbank.com/drugs/DB08860ApprovedInvestigationalclinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels. … This is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL
Aminosalicylic acid
go.drugbank.com/drugs/DB00233ApprovedInvestigationalAn antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
Limaprost
go.drugbank.com/drugs/DB09211InvestigationalLimaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. … numbness in the lower leg and walking disability associated with acquired lumbar spinal canal stenosis as an additional indication in 2001.
Categories: Prostaglandins ETrimethobenzamide
go.drugbank.com/drugs/DB00662ApprovedInvestigationalIn dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. … Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ).
Synonyms: N-[[4-(2-dimethylaminoethoxy)phenyl]methyl]-3,4,5-trimethoxybenzamideAprotinin
go.drugbank.com/drugs/DB06692ApprovedInvestigationalWithdrawnThe goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. … Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death.
Elbasvir
go.drugbank.com/drugs/DB11574ApprovedApproved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [ribavirin] depending on the presence of resistance-associated amino acid substitutions … [A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir was predicted to bind stably and preferentially to three proteins necessary for viral replication
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnNew Zealand and Canada have also followed suit in recalling the drug. … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigational[A264768] Acoramidis has been in development since at least 2013. … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.
Hyaluronidase (human recombinant)
go.drugbank.com/drugs/DB06205ApprovedInvestigational[A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.